Search for a trial

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

EFFICACY OBJECTIVESThe primary efficacy objective of this study is to evaluate the efficacy of intravitreal injections of 10 mg lampalizumab administered Q4W or Q6W in CFI profile biomarker positive and CFI profile biomarker-negative patients…

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

EFFICACY OBJECTIVESThe primary efficacy objective of this study is to evaluate the efficacy of intravitreal injections of 10 mg lampalizumab administered Q4W or Q6W in CFI profile biomarker positive and CFI profile biomarker-negative patients…

Investigation of the AcrySof® IQ PanOptix* Presbyopia Correcting IOL Model TFNT00

The objective of this investigation is to describe visual outcomes and assess the safety at 12 months (330 - 420 days) post bilateral implantation of the AcrySof® IQ PanOptix* Presbyopia correcting IOL Model TFNT00.

Clinical Investigation of Visual Function After Bilateral Implantation of Two Presbyopia-Correcting Trifocal IOLs.

Primary Objective:To demonstrate noninferiority of ACRYSOF IQ PanOptix presbyopia-correcting IOL Model TFNT00 to the AT LISA tri IOL Model 839MP in mean photopic binocular uncorrected intermediate (60 cm) visual acuity at Visit 4A.Secondary…

Global Multicenter Study with the Hydrophobic Acrylic (HF) Iris-Fixated PIOL for the Correction of Myopia in Phakic Eyes

The purpose of the study is to investigate the safety and effectiveness of the HF IF PIOL, and to compare performance with the Artiflex lens. Study outcomes will be used to obtain CE marking for the lens and for registration and marketing purposes.

protocol C-10-017: 'Lens Wearing Experience and Biocompatibility of a Marketed MPDS in Silicone Hydrogel and Soft Contact Lens Wearers'

The primary statistical objective of this study is to describe mean differences in corneal staining (type and area), for OPTI-FREE EverMoist Multi-Purpose Disinfecting Solution compared to baseline.

Pilot study to compare straylight perception in pseudophakic subjects with different intraocular lenses

The purpose of this pilot study is to compare the perception of straylight in patients with CE marked multifocal intraocular lenses, measured with 4 different straylight measuring devices..

A randomized, subject-blinded evaluation of visual function after bilateral implantation of two types of presbyopia-correcting multifocal IOLs

The objective of this study is to prospectively evaluate postoperative visual outcomes in a series of patients bilaterally implanted with the FineVision Micro F IOL versus those bilaterally implanted with the AcrySof® IQ ReSTOR® Aspheric +3 D…

A double blind randomized study on the efficacy of cyclopentolate 1% and cyclopentolate 1% with tropicamide 1% in children

To compare one dose of the short acting tropicamide combined with one dose of the longer acting cyclopentolate (c+t) with a double dose of the longer acting cyclopentolate (c+c). To develop a cycloplegics protocol that garantees optimal refractieve…

A Randomized, pilot study, subject-masked comparison of visual function after bilateral implantation of Presbyopia-correcting IOLs

The objective of this study is to prospectively evaluate postoperative visual outcome in a series of patients bilaterally implanted with the AcrySof® IQ ReSTOR® Aspheric +3 D multifocal IOL versus those bilaterally implanted with the LENTIS® Mplus…

Prospective multicenter clinical trial with the PRECIZION Presbyopic multifocal intraocular lens

The main objective of this study is to evaluate the ability of the PRECIZION Presbyopia IOL to provide near, intermediate and distance vision in patients undergoing cataract extraction and intraocular lens implantation. Study outcomes will be used…

A 64-week, two-arm, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patients with neovascular agerelated macular degeneration (TALON)

To evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control (TtC) regimen for the treatment of patients with neovascular age-related macular degeneration (nAMD) with the objective to evaluate the potential to reduce treatment…

An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multicenter, Phase III Study assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (RAVEN)

To evaluate the efficacy and safety of brolucizumab in the treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO) and its potential to reduce the treatment burden for patients.

Investigator led, double-masked, multicenter, randomized clinical trial for the comparison of Atropine 0.5% versus Atropine 0.05% eye drops for the prevention of myopia progression in Dutch children.

This study has been transitioned to CTIS with ID 2024-516379-34-00 check the CTIS register for the current data. Objectives:To compare the efficacy of Atropine 0.05% to Atropine 0.5% treatment in European children with progressive myopia, and to…

Childhood Atropine for Myopia Progression (CHAMP): A 3-Arm Randomized,
Double-Masked, Placebo-Controlled, Phase 3 Study of Atropine Sulfate Ophthalmic Solution 0.01%
and 0.02%

Primary Objective: To evaluate the safety and efficacy of 2 concentrations of Atropine Sulfate OphthalmicSolution (0.01% and 0.02%) compared to Vehicle (placebo) for slowing the progression of myopia inchildren over a 3-year treatment period.…

A 56-week phase IIIb/IV, open-label, one-arm extension study to assess the efficacy and safety of brolucizumab 6mg in a Treat-to-Control regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular Age-related Macular Degeneration who have completed the CRTH258A2303 (TALON) study

The purpose of this study is to evaluate the efficacy and safety of brolucizumab used in a Treat- to-Control (TtC) regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular age-related macular…

A phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter study of the
safety and efficacy of OT-101 (Atropine Sulfate 0.01%) in treating the progression of myopia in
pediatric subjects

To evaluate the efficacy of OT-101 Ophthalmic Solution in treating the progression of myopia in pediatric subjects following 3 years of treatment.To evaluate the safety and tolerability of OT-101 Ophthalmic Solution in pediatric subjects with myopia…

Post-Market Clinical Investigation of the Clareon® IOL

Primary Objective:The primary objective of this study is to demonstrate the long-term (3 years) favorable visual acuity and adverse event outcomes for the Clareon IOL compared to historical SPE rates as reported in EN ISO 11979-7:2014.Secondary…

A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A ROCHE-SPONSORED STUDY

The primary objective of this study is to evaluate the long-term safety and tolerability of ITV injections of 10 mg lampalizumab administered to patients with GA secondary to AMD as assessed by the:• Incidence and severity of ocular adverse events•…